OLMA Olema Pharmaceuticals, Inc.

QT14

Latest market price

7.00

-0.33-4.50%

Overview Short InterestFilings

OLMAQT14Olema Pharmaceuticals, Inc.·NASDAQ

Overview Short InterestFilings

7.00-4.50%

Loading chart...

Signal & projected range

Falling wedge — reversalHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

TRAX-0.33%$45.08 NVAX-3.72%$10.08 NUVB-0.21%$4.76 KLRA-4.10%$12.86 REPL+1.27%$17.61 STOK-0.23%$26.29 QURE-1.86%$24.83 NTLA-5.74%$12.47

Snapshot

Index	—	P/E	—	EPS (ttm)	-2.13	Insider Own	41.90%	Shs Outstand	87.50M	Perf Week	9.20%

Market Cap	612.48M	Forward P/E	—	EPS next Y	-2.66	Insider Trans	-0.07%	Shs Float	70.29M	Perf Month	-15.36%

Enterprise Value	152.48M	PEG	—	EPS next Q	-0.60			Short Float	22.31%	Perf Quarter	-37.94%

Income	-204.00M	P/S	—	EPS this Y	—			Short Ratio	14.52	Perf Half Y	-51.12%

Sales	0.00	P/B	1.42	EPS next Y	—	ROA	-42.04%	Short Interest	15.68M	Perf YTD	-72.00%

Book/sh	4.93	P/C	1.33	EPS next 5Y	—	ROE	-48.22%	52W High	36.26 -80.69%	Perf Year	-18.98%

Cash/sh	5.27	P/FCF	—	EPS past 3/5Y	—	ROIC	-50.92%	52W Low	6.24 12.18%	Perf 3Y	-43.32%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	7.89% 6.49%	Perf 5Y	-74.80%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	0.51	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	8.86	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	39.92	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	8.86	EPS Q/Q	-19.61%	SMA20	-3.25%	Beta	2.08	Target Price	28.33

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	—	SMA50	-20.80%	Rel Volume	0.63	Prev Close	7.33

Employees	150	LT Debt/Eq	0.00	Earnings	Nov 09	SMA200	-50.10%	Avg Volume	1.20M	Price	7.00

IPO Date	Nov 19, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-10.62% —	Net Debt/EBITDA	—	Volume	751,097	Change	-4.50%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-14-26	Reiterated	Stifel Nicolaus		$48 → $30
Aug-11-26	Reiterated	Goldman Sachs	Buy	$23 → $20
May-13-26	Reiterated	Guggenheim	Buy	$40 → $35
Mar-09-26	Reiterated	HC Wainwright & Co.	Buy	$45 → $38
Feb-10-26	Initiated	Stifel	Buy	$48
Jan-07-26	Initiated	Piper Sandler	Overweight	$40
Jan-07-26	Reiterated	UBS		$45
Dec-11-25	Reiterated	HC Wainwright & Co.	Buy	$36 → $45
Dec-11-25	Reiterated	Oppenheimer	Outperform	$48
Dec-11-25	Reiterated	Goldman Sachs	Buy	$26 → $38

Latest News· Times ET

Oct-19-26

Oct-19-2608:00AM

The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema OncologyYahoo

Oct-16-26

Oct-16-2610:46AM

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Monthzacks.com

Oct-14-26

Oct-14-2604:06AM

12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga

Oct-05-26

Oct-05-2610:31AM

SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsightYahoo

Oct-02-26

Oct-02-2604:30PM

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Sep-15-26

Sep-15-2604:41PM

Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com

Sep-10-26

Sep-10-2605:57PM

Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcriptseekingalpha.com

Sep-09-26

Sep-09-2610:30AM

Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1 '27SeekingAlpha

Sep-02-26

Sep-02-2604:30PM

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Aug-31-26

Aug-31-2604:30PM

Olema Oncology to Participate in Upcoming Investor Conferencesglobenewswire.com

04:31AM

66,163 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by Connor Clark & Lunn Investment Management Ltd.defenseworld.net

Aug-13-26

Aug-13-2607:28AM

JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46Benzinga

Aug-11-26

Aug-11-2602:27PM

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027benzinga.com

Aug-10-26

Aug-10-2601:06PM

12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga

Aug-04-26

Aug-04-2604:30PM

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Company

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	0	—	—	—	—	—
Gross Profit	0	0	0	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	31	21	18	19	—	—	—	—	—
Research and Development	190	158	125	86	—	—	—	—	—
Other Operating Expense	0	0	-1	0	—	—	—	—	—
Operating Income	-221	-179	-142	-105	—	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	17	16	13	8	—	—	—	—	—
Net Income Before Taxes	-204	-162	-129	-97	—	—	—	—	—
Income Taxes	0	0	0	0	—	—	—	—	—
Consolidated Net Income	-204	-162	-129	-97	—	—	—	—	—
Net Income From Continuing Operations	-204	-162	-129	-97	—	—	—	—	—
Net Income	-204	-162	-129	-97	—	—	—	—	—
EPS (Recurring)	-2.12	-1.87	-2.20	-2.14	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-2.12	-1.87	-2.20	-2.14	—	—	—	—	—
EPS (Diluted)	-2.13	-1.87	-2.20	-2.14	—	—	—	—	—
EBITDA	-204	-162	-129	-96	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	104	87	59	45	—	—	—	—	—
Market Capitalization	728	2,175	344	631	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Harmon Cyrus	Director	Jul 24 '26	Sale	11.71	12,500	146,425	702,770	Jul 27
Harmon Cyrus	Director	Jul 23 '26	Sale	11.58	12,500	144,738	715,270	Jul 27
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 04 '26	Sale	24.25	25,000	606,353	0	Mar 05
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 04 '26	Option Exercise	4.37	25,000	109,250	25,000	Mar 05
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 03 '26	Option Exercise	4.37	15,000	65,550	15,000	Mar 05
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 03 '26	Sale	23.01	15,000	345,150	0	Mar 05
Harmon Cyrus	Director	Jan 20 '26	Sale	26.88	10,000	268,800	727,770	Jan 21
Harmon Cyrus	Director	Jan 14 '26	Sale	29.12	3,489	101,600	737,770	Jan 16
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Jan 15 '26	Sale	28.73	100,000	2,873,000	139,727	Jan 15
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Jan 13 '26	Sale	28.01	3,822	107,054	239,727	Jan 15
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 14 '26	Sale	28.87	50,000	1,443,651	542,761	Jan 14
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 14 '26	Option Exercise	4.87	50,000	243,500	592,761	Jan 14
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 13 '26	Sale	27.60	50,000	1,380,178	542,761	Jan 14
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 13 '26	Option Exercise	4.87	50,000	243,500	100,000	Jan 14
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 12 '26	Sale	28.34	10,000	283,400	144,846	Jan 14

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.